直接抗病毒药物联合PR方案（PEG-IFN联合利巴韦林）在丙型肝炎抗病毒治疗新时代的价值

陈新月; 柳雅立; 任姗

doi:10.3969/j.issn.1001-5256.2017.06.009

直接抗病毒药物联合PR方案（PEG-IFN联合利巴韦林）在丙型肝炎抗病毒治疗新时代的价值

DOI: 10.3969/j.issn.1001-5256.2017.06.009

首都医科大学附属北京佑安医院

基金项目:

首都临床特色应用研究(Z151100004015181,Z161100000516018)；首都卫生发展科研重点专项(首发2016-1-218-3)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 3259
- HTML全文浏览量: 22
- PDF下载量: 485
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C

Research funding:

摘要

摘要: PEG-IFN联合利巴韦林（PR方案）在中国已有10多年的使用经验,随着直接抗病毒药物（DAA）的发展,丙型肝炎治疗方案出现多元化。DAA联合PR方案,在保留IFN有利慢性丙型肝炎（CHC）患者长期预后等优势的前提下使用DAA,可提高疗效、缩短疗程,进一步改善CHC的治疗现状。介绍PR、DAA联合PR及DAA全口服方案的优劣,旨在探讨更适合不同CHC患者的治疗方案,为临床实践提供参考。
- 肝炎,丙型,慢性 /
- 抗病毒药 /
- 治疗
Abstract: Pegylated interferon (PEG-IFN) combined with ribavirin (PR regimen) has been used in China for more than 10 years. With the development of direct-acting antiviral agents (DAAs) , the therapeutic regimens for hepatitis C has become more and more diverse. In the regimen of DAAs combined with PR regimen, IFN helps to benefit the long-term prognosis of patients with chronic hepatitis C (CHC) , and the addition of DAAs may improve therapeutic effect, shorten the course of treatment, and further improve the current status of treatment of CHC. This article introduces the advantages and disadvantages of PR regimen, DAAs combined with PR regimen, and oral regimen with DAAs, in order to investigate the therapeutic regimens suitable for different CHC patients and provide a reference for clinical practice.
- hepatitis C, chronic /
- antiviral agents /
- therapy

HTML全文

参考文献(39)

[1]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.

[2]SIEVERT W, ALTRAIF I, RAZAVI HA, et al.A systematic review of hepatitis C virus epidemiology in asia, australia and egypt[J].Liver Int, 2011, 31 (Suppl 2) :61-80.

[3]DUAN Z, JIA JD, HOU J, et al.Current challenges and the management of chronic hepatitis C in mainland China[J].J Clin Gastroenterol, 2014, 48 (8) :679-686.

[4]RAO H, WEI L, LOPEZ-TALAVERA JC, et al.Distribution and clinical correlates of viral and host genotypes in chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[5]Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[6]CHEN XY, SHANG J, YANG RF, et al.High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na (i) ve patients:a multicenter randomized study[J].Chin J Hepatol, 2015, 23 (6) :412-417. (in Chinese) 陈新月, 尚佳, 杨瑞锋, 等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究[J].中华肝脏病杂志, 2015, 23 (6) :412-417.

[7]D'AMBROSIO R, AGHEMO A, RUMI MG, et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology, 2012, 56 (2) :532-543.

[8]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis[J].JAMA, 2012, 308 (24) :2584-2593.

[9]HAGIHARA H, NOUSO K, KOBAYASHI Y, et al.Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma[J].Int J Clin Oncol, 2011, 16 (3) :210-220.

[10]LIU Z, WEI X, CHEN T, et al.Characterization of fibrosis changes in chronic hepatitis C patients after virological cure:a systematic review with meta-analysis[J].J Gastroenterol Hepatol, 2017, 32 (3) :548-557.

[11]WEI L, LI J, YANG X, et al.Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China[J].J Gastroenterol Hepatol, 2016, 31 (12) :1995-2003.

[12]YU ML, YEH ML, TSAI PC, et al.Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C:a nationwide survey in Taiwan[J].Medicine (Baltimore) , 2015, 94 (13) :e690.

[13]BERTINO G, ARDIRI A, PROITI M, et al.Chronic hepatitis C:this and the new era of treatment[J].World J Hepatol, 2016, 8 (2) :92-106.

[14]SCHINAZI R, HALFON P, MARCELLIN P, et al.HCV directacting antiviral agents:the best interferon-free combinations[J].Liver Int, 2014, 34 (Suppl 1) :69-78.

[15]de CLERCQ E.Current race in the development of DAAs (directacting antivirals) against HCV[J].Biochem Pharmacol, 2014, 89 (4) :441-452.

[16]WEI L, ZHANG M, XU M, et al.A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J].J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.

[17]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int, 2016, 10 (5) :702-726.

[18]HNER ZU SIEDERDISSEN C, MAASOUMY B, MARRA F, et al.Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J].Clin Infect Dis, 2016, 62 (5) :561-567.

[19]Hepatitis C treatments containing sofosbuvir in combination with another direct acting antiviral drug:drug safety communication-serious slowing of heart rate when used with antiarrhythmic drug amiodarone[EB/OL].[2015-03-24].http://www.fda.gov/Safety/Med Watch/Safety Information/Safety Alertsfor Human Medical Products/ucm439662.htm.

[20]FDA Drug Safety Communication:FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie[EB/OL].[2015-10-22].http://www.fda.gov/Drugs/Drug Safety/ucm468634.htm&source=govdelivery&utm_medium=email&utm_source=govdelivery.

[21]Revisions of precautions (FY2016) [EB/OL].http://www.pmda.go.jp/english/safety/info-services/drugs/revision-of-precautions/0004.html.

[22]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[23]REIG M, MARIO Z, PERELLC, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.

[24]CARDOSO H, VALE AM, RODRIGUES S, et al.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis[J].J Hepatol, 2016, 65 (5) :1070-1071.

[25]WANG C, JI D, CHEN J, et al.Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.

[26]FDA Drug Safety Communication:FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C[EB/OL].[2016-10-04].http://www.fda.gov/drugs/drugsafety/ucm522932.htm.

[27]WANG C, LI B, CHEN J, et al.Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus:a systematic review and meta-analysis[C].Boston:AASLD, 2016.

[28]HOOFNAGLE JH, SEEFF LB.Peginterferon and ribavirin for chronic hepatitis C[J].N Engl J Med, 2006, 355 (23) :2444-2451.

[29]YAN LB, RAO HY, MA YJ, et al.Hepatitis B virus infection in Chinese patients with hepatitis C virus infection:prevalence, clinical characteristics, viral interactions and host genotypes:a nationwide cross-sectional study[J].BMJ Open, 2016, 6 (10) :e012016.

[30]ISAACS A, LINDENMANN J.Virus interference.I.The interferon[J].Proc R Soc Lond B Biol Sci, 1957, 147 (927) :258-267.

[31]LINDAHL P, LEARY P, GRESSER I.Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes[J].Proc Natl Acad Sci U S A, 1972, 69 (3) :721-725.

[32]EINHORN S, STRANDER H.Is interferon tissue specific?-Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines[J].J Gen Virol, 1977, 35 (3) :573-577.

[33]Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395.

[34]KAO JH, TUNG SY, LEE Y, et al.Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis[J].J Gastroenterol Hepatol, 2016, 31 (10) :1757-1765.

[35]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 368 (20) :1878-87.

[36]WEI L, HAN T, YANG D, et al.Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-na6ve patients in China and South Korea[J].J Gastroenterol Hepatol, 2016, 31 (5) :912-920.

[37]WEI L.Makalu:twelve-week of treatment with ritonavir-boosted danoprevir plus peginterferon and ribavirin produces 96%SVR12 in HCV genotype 1-infected non-cirrhotic chinese patients[R].Shanghai:APASL, 2017.

[38]RUTTER K, HOFER H, BEINHARDT S, et al.Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral[J].Aliment Pharmacol Ther, 2013, 38 (2) :118-123.

[39]BROGAN AJ, TALBIRD SE, THOMPSON JR, et al.Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C[J].PLo S One, 2014, 9 (3) :e90295.

施引文献

资源附件(0)

访问统计